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the more oxygen is consumed, the more 
likely it is that reactive oxygen intermediates 
are generated. This new hypothesis requires 
rigorous future testing. See page 197.
New model of mineral 
bone disease in CKD
 Recent studies have shown a new syndrome 
of bone disease in patients with chronic 
kidney disease (CKD) who also have 
vascular calcification and abnormalities 
in serum calcium phosphorus and par-
athyroid hormone. This new syndrome is 
associated with a high rate of morbidity 
and mortality. Now, Moe et al. describe 
a new model of this syndrome, the Cy/+ 
rat, which spontaneously develops slowly 
progressive kidney disease. These animals 
were fed a normal phosphorus diet but dif-
ferent sources of protein (casein-based or 
grain-based). The casein-based diet resulted 
in more severe progression of CKD and 
mineral bone disease, possibly due to the 
different bioavailability of dietary phos-
phorus. While both diets resulted in the 
same serum inorganic phosphate levels, 
the casein-fed animals had higher urinary 
New functions for AII
The discovery that blocking the renin–
angiotensin system can delay progression 
of CKD is one of the greatest advances in 
nephrology. The mechanism by which 
this blockade exerts its beneficial effect 
was initially thought to be, in large part, 
due to angiotensin’s vascular effect and/
or its function as a growth factor. How-
ever, angiotensin II (AII) also stimulates 
sodium (Na) reabsorption in the proxi-
mal tubule by increasing the activity of the 
Na:H exchanger. The magnitude of this 
effect is not easy to demonstrate in vivo. 
The kidney’s oxygen consumption is very 
large, and most of it is due to mediating Na 
reab sorption. Deng et al. present results 
of a new study in which they blocked the 
effect of AII using a combination of losartan 
and captopril in the remnant kidney model 
and measured renal oxygen consumption. 
Surprisingly, the amount of oxygen con-
sumed increased per unit of Na reabsorbed. 
The reason for an angiotensin-mediated 
increase in Na reabsorption in renal fail-
ure is not clear; one possibility is that AII 
produces hyperfiltration that increases Na 
delivery, thus increasing Na reabsorption. 
However, simply increasing filtration and 
delivery would not increase the ratio of 
oxygen consumption per unit of Na reab-
sorbed. Hence, it is likely that increased Na 
delivery per nephron resulting in increased 
Na reabsorption is mediated by AII. Could 
this be a new mechanism of AII ‘toxicity’ in 
renal failure? Increased oxygen consump-
tion per nephron might be a culprit, since 
phosphate excretion and elevated serum 
FGF23 levels. This model is a welcome 
addition to the study of this new syndrome. 
See page 176.
Renal volume changes 
in ADPKD
The growth of the size of the kidney is 
perhaps the best marker for following the 
progression of autosomal dominant poly-
cystic kidney disease (ADPKD). We are in 
the hopeful position of testing several new 
therapies that have been beneficial in ani-
mal models; the question now arises of the 
sensitivity of the methods used to rapidly 
assess changes in kidney volume in these 
models. In a study published this issue, 
Kistler et al. used MRI volume measure-
ments to gauge changes in renal volume in 
100 young patients with ADPKD and nor-
mal renal function over a 6-month period. 
Because of concern about the effect of gado-
linium on renal function, these studies were 
performed with an optimized T1-weighted 
acquisition protocol without gadolinium-
based contrast agents. Within 6 months, the 
patients’ kidney volumes increased by 2.7%. 
More significantly, the measurements were 
reproducible using inter-observer and intra-
observer data. Further, as expected, a good 
correlation was found between reduced 
renal function or proteinuria and increased 
renal volume. These studies should provide 
a useful baseline for future therapeutic stud-
ies of ADPKD. See page 235.
It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
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